Clinical Trial Update: Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating BCD-263 and Opdivo as monotherapy for advanced melanoma of the skin; the study status is ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BCD-263
• OPDIVO (nivolumab)

Snippet

Sponsor: Biocad | Conditions: Advanced Melanoma, Melanoma (Skin) | Phase 3 | Status: ACTIVE_NOT_RECRUITING